T. Rowe Price Associates’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $187K | Buy |
48,683
+13,600
| +39% | +$52.2K | ﹤0.01% | 2735 |
|
|
2025
Q1 | $202K | Buy |
35,083
+2,978
| +9% | +$17.1K | ﹤0.01% | 2631 |
|
|
2024
Q4 | $161K | Sell |
32,105
-23,517
| -42% | -$118K | ﹤0.01% | 2743 |
|
|
2024
Q3 | $300K | Buy |
55,622
+7,149
| +15% | +$38.6K | ﹤0.01% | 2476 |
|
|
2024
Q2 | $161K | Buy |
48,473
+200
| +0.4% | +$664 | ﹤0.01% | 2642 |
|
|
2024
Q1 | $158K | Buy |
48,273
+3,446
| +8% | +$11.3K | ﹤0.01% | 2686 |
|
|
2023
Q4 | $158K | Buy |
44,827
+4,935
| +12% | +$17.4K | ﹤0.01% | 2608 |
|
|
2023
Q3 | $267K | Buy |
39,892
+742
| +2% | +$4.97K | ﹤0.01% | 2380 |
|
|
2023
Q2 | $329K | Sell |
39,150
-10,437
| -21% | -$87.7K | ﹤0.01% | 2319 |
|
|
2023
Q1 | $493K | Hold |
49,587
| – | – | ﹤0.01% | 2112 |
|
|
2022
Q4 | $345K | Buy |
49,587
+15,200
| +44% | +$106K | ﹤0.01% | 2320 |
|
|
2022
Q3 | $184K | Sell |
34,387
-10,923
| -24% | -$58.4K | ﹤0.01% | 2573 |
|
|
2022
Q2 | $181K | Sell |
45,310
-1,054
| -2% | -$4.21K | ﹤0.01% | 2623 |
|
|
2022
Q1 | $206K | Buy |
46,364
+9,300
| +25% | +$41.3K | ﹤0.01% | 2693 |
|
|
2021
Q4 | $148K | Buy |
37,064
+25,900
| +232% | +$103K | ﹤0.01% | 2811 |
|
|
2021
Q3 | $98K | Sell |
11,164
-100
| -0.9% | -$878 | ﹤0.01% | 2843 |
|
|
2021
Q2 | $128K | Buy |
+11,264
| New | +$128K | ﹤0.01% | 2804 |
|